Risk Assessment of Progressive Multifocal Leukoencephalopathy in Multiple Sclerosis Patients during 1 Year of Ocrelizumab Treatment

MLA

Carla Prezioso, et al. “Risk Assessment of Progressive Multifocal Leukoencephalopathy in Multiple Sclerosis Patients during 1 Year of Ocrelizumab Treatment.” Viruses, vol. 13, no. 9, Aug. 2021, p. 1684. EBSCOhost, https://doi.org/10.3390/v13091684.

APA

Carla Prezioso, Alfonso Grimaldi, Doriana Landi, Carolina Gabri Nicoletti, Gabriele Brazzini, Francesca Piacentini, Sara Passerini, Dolores Limongi, Marco Ciotti, Anna Teresa Palamara, Girolama Alessandra Marfia, & Valeria Pietropaolo. (2021). Risk Assessment of Progressive Multifocal Leukoencephalopathy in Multiple Sclerosis Patients during 1 Year of Ocrelizumab Treatment. Viruses, 13(9), 1684. https://doi.org/10.3390/v13091684

Chicago

Carla Prezioso, Alfonso Grimaldi, Doriana Landi, Carolina Gabri Nicoletti, Gabriele Brazzini, Francesca Piacentini, Sara Passerini, et al. 2021. “Risk Assessment of Progressive Multifocal Leukoencephalopathy in Multiple Sclerosis Patients during 1 Year of Ocrelizumab Treatment.” Viruses 13 (9): 1684. doi:10.3390/v13091684.